Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway.
Qiang Li,Mengxiao Jia,Zhencheng Yan,Qiang Li,Fang Sun,Chengkang He,Yingsha Li,Xunmei Zhou,Hexuan Zhang,Xiaoli Liu,Xiaona Bu,Peng Gao,Hongbo He,Zhigang Zhao,Zhiming Zhu
DOI: https://doi.org/10.1161/jaha.120.020734
IF: 6.106
2021-07-14
Journal of the American Heart Association
Abstract:Background Patients with hypertension and diabetes mellitus are susceptible to dementia, but regular therapy fails to reduce the risk of dementia. Glucagon‐like peptide‐1 receptor agonists have neuroprotective effects in experimental studies. We aimed to assess the effect of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on cognitive function and whether its effect was associated with metabolic changes in patients with type 2 diabetes mellitus. Methods and Results Fifty patients with type 2 diabetes mellitus were recruited in this prospective study. All patients underwent cognitive assessment and brain activation monitoring by functional near‐infrared spectroscopy. At 12 weeks, patients in the glucagon‐like peptide‐1 group acquired better scores in all cognitive tests and showed remarkable improvement in memory and attention ( P =0.040) test compared with the control group after multivariable adjustment. Compared with the control group, liraglutide significantly increased activation of the dorsolateral prefrontal cortex and orbitofrontal cortex brain regions ( P =0.0038). After liraglutide treatment, cognitive scores were significantly correlated with changes in these activating brain regions ( P <0.05), but no correlation was observed between the changes in cognitive function and changes of body mass index, blood pressure, and glycemic levels. Conclusions We concluded that liraglutide improves cognitive decline in patients with type 2 diabetes mellitus. This beneficial effect is independent of its hypoglycemic effect and weight loss. The optimal intervention should be targeted to cognitive decline in the early stages of dementia. Registration URL: https://www.ClinicalTrials.gov ; Unique identifier: NCT03707171. Nonstandard Abbreviations and Acronyms DLPFC dorsolateral prefrontal cortex fNIRS functional near‐infrared spectroscopy GLP‐1 RAs glucagon‐like peptide‐1 receptor agonists MMSE Mini‐Mental State Examination OFC orbitofrontal cortex VFT verbal fluency task Clinical Perspective What Is New? We examined liraglutide‐related cognitive improvement and demonstrated its neuroprotective effect in patients with diabetes mellitus without severe obesity. Liraglutide significantly improved brain activities and alleviated cognitive decline in patients with diabetes mellitus, compared with other oral antidiabetic drugs. The neuroprotective effect of liraglutide was not related to metabolic improvement, including blood pressure, blood lipids, glycemia. and body weight in patients with diabetes mellitus. What Are the Clinical Implications? This study provided evidence of glucagon‐like peptide‐1 effects on the central nervous system in patients with diabetes mellitus. Early liraglutide treatment might have a beneficial effect on cognitive decline in patients with diabetes mellitus. Glucagon‐like peptide‐1 receptor agonists might be promising drugs to improve cognitive dysfunction, however, these findings need to be confirmed in randomized controlled trials. Alzheimer disease (AD) is highly prevalent worldwide. 1 Type 2 diabetes mellitus (T2DM), hypertension, and obesity have been recognized as major risk factors for cognitive decline and AD. 2 Importantly, patients with hypertension with diabetes mellitus usually display features of cognitive decline, such as defects in verbal memory and fluency, attention, and executive function. 3 The underlying mechanism linking metabolic disorders and cognitive decline remains elusive although numerous studies have suggested that vascular and/or metabolic dysfunction might be involved. <sup -Abstract Truncated-
cardiac & cardiovascular systems